Open access
Jul 2026
Cross-neutralization of SARS-CoV-2 BA.3.2.2 lineage by JN.1 mRNA vaccine-induced immunity.
BA.3.3.2.2 preserves class 1/2 antibody epitopes, providing a mechanistic basis for cross-neutralization and suggesting a potential therapeutic window for sipavibart should BA.3.3.2.2 expand globally, pending clinical confirmation.
Kei Miyakawa, Kaori Sano, Yohei Seki et al.
· International Journal of Inf... · 0 citations